CHChandni Hindocha

Chandni Hindocha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects


Chandni Hindocha has a total of 213 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Cannabis Research Image Database (CRESIDA): a standardized and validated image set for studying cannabis cue-reactivity

    by Janna Cousijn, Emese Kroon, Chao Suo, Tom Freeman, Chandni Hindocha, Marianna Quinones-Valera, Valentina Lorenzetti

    Background and Aims: Cannabis cue-reactivity paradigms are instrumental in studying the behavioral and neurocognitive mechanisms of cannabis use and cannabis use disorders. However, image sets used for cannabis cue-reactivity paradigms vary between studies, and the lack of reliability and validity assessment hinders the quality of evidence they generate. The main aim of this study was to create a novel, open access, standardized, and representative database of cannabis use-related images including control images matched by resolution, luminosity, and complexity: The Cannabis Research Image Database (CRESIDA). The secondary aim was to examine whether subjective cannabis cue-induced craving was associated with cannabis‑use severity and whether this relationship was moderated by image type. As an illustrative example of how our open data can be used and how sample characteristics can shape cue‑reactivity, we also explored the role of cannabis–tobacco mixing by comparing cannabis cue-induced cannabis and tobacco craving between individuals who did and did not mix the substances. Design: An online survey was administered to participants recruited via online platforms, community advertisement, and snowballing. Setting: USA, the Netherlands, and Australia. Participants/Cases: 689 participants who consumed cannabis monthly-to-daily (385 men, 298 women, 6 other) were recruited between January 2022 and May 2024. Measurements: Out of 93 cannabis images and 93 matched neutral images, participants each rated 31 image pairs for cannabis craving (the primary outcome), arousal, valence, and tobacco craving. Participants were characterized for socio-demographic data, level of cannabis use and related problems, and mixing cannabis and tobacco. A subset of 78 images was selected for further analysis based on cannabis craving results. Image ratings were evaluated for internal consistency (). Furthermore, we examined the association between cannabis cravings and cannabis use characteristics, and explored if cannabis craving ratings were affected by image type (i.e., product, paraphernalia, and actions), and by using cannabis alone vs. mixing cannabis and tobacco. Findings. The database showed excellent reliability ( = .995-.965). Cannabis craving, valence, and arousal discriminated cannabis and control images. More cannabis use days (β = 0.162, p < 0.001) and cannabis-related problems (β = 0.268, p < 0.001) were significantly associated with higher image-related cannabis craving. Mixing cannabis with tobacco, compared to using cannabis alone, was associated with the presence of tobacco craving in relation to cannabis images, and with greater cannabis craving in relation to cannabis images (β = -0.457, p < 0.001). Conclusions: Images part of the open access CRESIDA (https://osf.io/dc9nz/) are reliable and valid for the scientific study of cue-reactivity internationally, providing a broad range of free to use cannabis and control images.

  • Open Access

    A taxonomy of reward processing and associations with problematic alcohol use in young, hazardous drinkers

    by Louise Simeonov, Vincent Valton, Chandni Hindocha, Arjan Raja, Sukran Cagatayli, Davide Bono, Nick Klein, Tom Freeman, Jonathan Paul Roiser, Val Curran, et al.

    BackgroundMultiple theories of substance use disorder postulate an imperative role of reward processing in problematic alcohol use. However, it is unknown how different facets of reward processing converge; what underlying latent variables they represent; and how they are associated with alcohol use. MethodsSixty-three young hazardous drinkers completed self-report questionnaire (e.g. anhedonia) and behavioural task reward-related measures in an exploratory, cross-sectional study. Principle component analyses (PCA) were used to explore the underlying structure of the measures. PCA factors were correlated with measures of alcohol use. Computational analyses were employed for a subgroup of the behavioural tasks and extracted parameters correlated with measures of alcohol use.ResultsThe PCAs revealed several distinct facets of reward processing. The factors from the task PCA reflected: reward valuation, frustrative non-reward, reward/punishment bias, loss aversion, consummatory anhedonia & reinforcement learning, and risk aversion. The factors from the questionnaire PCA reflected: apathy/anhedonia, and depression & anxiety. The depression & anxiety factor was negatively associated with number of units consumed (r=-0.28, p=0.026, uncorrected) and reward/punishment bias factor was negatively associated with AUDIT (Alcohol use disorder identification test) score (r=0.30, p=0.016, uncorrected). The reinforcement learning parameter extracted from the bandit task negatively correlated with AUDIT score (r=-0.35, p=0.004, uncorrected).ConclusionsWe provide an empirically based taxonomy of reward processing in young hazardous drinkers, which demonstrates the separable reward-related constructs. Reinforcement learning, reward/punishment bias, and negative affect (depression & anxiety) are all tentatively negatively associated with problematic alcohol use.

  • Open Access

    Co-Use, Simultaneous Use, and Mixing of Cannabis and Tobacco: A Cross-national Comparison of Canada and the US by Cannabis Administration Type

    by Alanna Chu, Michael Chaiton, Pamela Kaufman, Renee Goodwin, Jodie Lin, Chandni Hindocha, Samantha Goodman, David Hammond

    Introduction: Increasing cannabis legalization raises concerns that tobacco use, frequently used with cannabis, will also increase. This study investigated the association between legal status of cannabis in place of residence and prevalence of cannabis and tobacco co-use, simultaneous use, and mixing by comparing the prevalence among adults in Canada (prior to cannabis legalization) vs. adults in US states that had legalized recreational cannabis vs. US states that had not as of September 2018. Methods: Data were drawn from the 2018 International Cannabis Policy Study, conducted with respondents aged 16-65 in Canada and the US recruited from non-probability consumer panels. Differences in the prevalence of co-use, simultaneous use, and mixing between tobacco and different cannabis products were examined using logistic regression models by legal status of place of residence among past 12-month cannabis consumers (N=6744). Results: Co-use and simultaneous use in the past 12 months were most common among respondents in US legal states. Among cannabis consumers, co-use and simultaneous use were less common in US legal states, while mixing was less frequent in US states with both legal and illegal cannabis compared to Canada. Use of edibles was associated with lower odds of all three outcomes, while smoking dried herb or hash was associated with higher odds. Conclusions: The proportion of cannabis consumers who used tobacco was lower in legal jurisdictions despite higher prevalence of cannabis use. Edible use was inversely associated with co-use suggesting that edible use does not appear to be associated with increased tobacco use.


  • The iCannTookit: a consensus‐based, flexible framework for measuring contemporary cannabis use

    by Valentina Lorenzetti, Chandni Hindocha, Kat Petrilli, Paul Griffiths, Jamie Brown, Álvaro Castillo‐Carniglia, Jonathan P. Caulkins, Amir Englund, Mahmoud A. El Sohly, Suzanne H. Gage, et al.


  • P.0586 Effects of cannabidiol (CBD) alone and combined with Δ9-tetrahydrocannabinol (THC) on functional connectivity of the pain-matrix

    by N. Ertl, M. Wall, R. Pope, T. Freeman, L. Demetriou, Z. Yang, D. Solomons, C. Mokrysz, C. Hindocha, W. Lawn, et al.

  • Open Access

    The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use

    by Valentina Lorenzetti, Chandni Hindocha, Kat Petrilli, Paul Griffiths, Jamie Brown, Álvaro Castillo‐Carniglia, Jonathan P. Caulkins, Amir Englund, Mahmoud A. ElSohly, Suzanne H. Gage, et al.

    Background: The lack of an agreed international minimum approach to measuring cannabis use hinders the integration of multidisciplinary evidence on the psychosocial, neurocognitive, clinical and public health consequences of cannabis use.Methods: A group of 25 international expert cannabis researchers convened to discuss a multidisciplinary framework for minimum standards to measure cannabis use globally in diverse settings.Results: The expert‐based consensus agreed upon a three‐layered hierarchical framework. Each layer—universal measures, detailed self‐report and biological measures—reflected different research priorities and minimum standards, costs and ease of implementation. Additional work is needed to develop valid and precise assessments.Conclusions: Consistent use of the proposed framework across research, public health, clinical practice and medical settings would facilitate harmonisation of international evidence on cannabis consumption, related harms and approaches to their mitigation.


  • The Effects of Acute Δ9-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study

    by Michael A.P. Bloomfield, Katherine Petrilli, Rachel Lees, Chandni Hindocha, Katherine Beck, Ryan J. Turner, Ellis Chika Onwordi, Neil Rane, David J. Lythgoe, James M. Stone, et al.


  • Open Access

    Stimulating meditation: a pre-registered randomised controlled experiment combining a single dose of the cognitive enhancer, modafinil, with brief mindfulness training

    by Emily M Thomas, Tom P Freeman, Patrick Poplutz, Kane Howden, Chandni Hindocha, Michael Bloomfield, Sunjeev K Kamboj

    Background: Mindfulness-meditation has a variety of benefits on well-being. However, individuals with primary attentional impairments (e.g. attention deficit disorder) or attentional symptoms secondary to anxiety, depression or addiction, may be less likely to benefit, and require additional mindfulness-augmenting strategies. Aims: To determine whether a single dose of the cognitive enhancer, modafinil, acutely increases subjective and behavioural indices of mindfulness, and augments brief mindfulness training. Methods: A randomised, double-blind, placebo-controlled, 2 (drug: placebo, modafinil) × 2 (strategy: mindfulness, relaxation control) experiment was conducted. Seventy-nine meditation-naïve participants were assigned to: placebo–relaxation, placebo–mindfulness, modafinil–relaxation or modafinil–mindfulness. Pre-drug, post-drug and post-strategy state mindfulness, affect and autonomic activity, along with post-strategy sustained attention and mind-wandering were assessed within a single lab session. After the session, participants were instructed to practice their assigned behavioural strategy daily for one week, with no further drug administration, after which, follow-up measures were taken. Results: As predicted, modafinil acutely increased state mindfulness and improved sustained attention. Differential acute strategy effects were found following mindfulness on autonomic activity but not state mindfulness. There were no strategy or drug effects on mind-wandering. However, exploratory analyses indicated that participants receiving modafinil engaged in more strategy practice across strategy conditions during follow-up. Conclusions: Modafinil acutely mimicked the effects of brief mindfulness training on state mindfulness but did not enhance the effects of this training. Limitations of the current study, and recommendations for future research examining modafinil as an adjunct to mindfulness- (or relaxation-) based treatments are discussed.


  • Open Access

    Cannabis based medicines and cannabis dependence: A critical review of issues and evidence

    by Anne K Schlag, Chandni Hindocha, Rayyan Zafar, David J Nutt, H Valerie Curran

    Cannabis has been legalised for medical use in an ever-increasing number of countries. A growing body of scientific evidence supports the use of medical cannabis for a range of therapeutic indications. In parallel with these developments, concerns have been expressed by many prescribers that increased use will lead to patients developing cannabis use disorder. Cannabis use disorder has been widely studied in recreational users, and these findings have often been projected onto patients using medical cannabis. However, studies exploring medical cannabis dependence are scarce and the appropriate methodology to measure this construct is uncertain. This article provides a narrative review of the current research to discern if, how and to what extent, concerns about problems of dependence in recreational cannabis users apply to prescribed medical users. We focus on the main issues related to medical cannabis and dependence, including the importance of dose, potency, cannabinoid content, pharmacokinetics and route of administration, frequency of use, as well as set and setting. Medical and recreational cannabis use differs in significant ways, highlighting the challenges of extrapolating findings from the recreational cannabis literature. There are many questions about the potential for medical cannabis use to lead to dependence. It is therefore imperative to address these questions in order to be able to minimise harms of medical cannabis use. We draw out seven recommendations for increasing the safety of medical cannabis prescribing. We hope that the present review contributes to answering some of the key questions surrounding medical cannabis dependence.


  • Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis

    by Abigail M Freeman, Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia Ja Morgan, Tom P Freeman, Rob Saunders, H Valerie Curran

    Background: While the acute effects of cannabis are relatively benign for most users, some individuals experience significant adverse effects. This study aimed to identify whether variation in schizotypal personality traits and frequency of cannabis use influence the acute effects of delta-9-tetrahydrocannabinol (THC). Methods: Individual participant data from four double-blind, randomised, placebo-controlled, acute crossover studies involving 128 cannabis users were combined for a mega-analysis. Using multilevel linear models and moderation analyses, frequency of cannabis use and schizotypal personality traits were investigated as potential moderators of the subjective, cognitive and psychotomimetic effects of acute THC. Results: There was evidence of a moderating effect where increased frequency of cannabis use was associated with reduced intensity of subjective (changes in alertness and feeling stoned) and psychosis-like effects following THC when compared with placebo. Moderating effects of cannabis use frequency on acute memory impairment were weak. Trait schizotypy did not moderate the acute psychosis-like effects of THC compared with placebo. Conclusions: Our results suggest that a pattern of domain-specific tolerance develops to the acute effects of THC. Tolerance to the alertness-reducing effects occurred more readily than tolerance to psychotomimetic effects. Only partial tolerance to feeling stoned was found, and there was weak evidence for tolerance to memory impairment. Trait schizotypy did not moderate THC’s effects on psychotomimetic symptoms.